Recent progress in the treatment of idiopathic aldosteronism
10.3760/cma.j.issn.1000-6699.2012.02.022
- VernacularTitle:特发性醛固酮增多症的治疗进展
- Author:
Jianfei CAI
;
Weiqing WANG
- Publication Type:Journal Article
- Keywords:
Hyperaldosteronism;
Aldosterone-synthase inhibitor;
Eplerenone;
Spironolactone
- From:
Chinese Journal of Endocrinology and Metabolism
2012;28(2):168-170
- CountryChina
- Language:Chinese
-
Abstract:
The bilateral idiopathic aldosteronism (IHA) is the most common subtype of aldosteronism.Spironolactone is the primary preferred agent due to the pathophysiology of IHA and the long-standing clinical experience over years.If patients faced with severe side effects of spironolactone or poorly controlled blood pressure by this first-line treatment,additional treatment alternative to spironolactone,second antihypertensive,as well as adrenalectomy are suggested.In recent years,several new agents were developed to treat IHA,such as aldosterone synthase inhibitor and eplerenone.This review introduces these new kinds of medicine in the treatment of IHA.
